CRNX Stock — Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc. (CRNX)

Updated September 2, 2026.

CRNX is a Stock. Total return is 246.6% over the past 8.1 years, 39.1 points ahead of SPY at 207.5%.

Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company developing novel therapeutics for rare endocrine diseases and endocrine-related tumors, with its lead candidate Paltusotine in Phase 3 trials for acromegaly and carcinoid syndrome, alongside a pipeline of earlier-stage programs targeting conditions including Cushing's disease, Graves' disease, primary hyperparathyroidism, and obesity. The company does not currently distribute to shareholders. Crinetics appeals to investors seeking exposure to clinical-stage biotech with a focus on rare endocrine disorders, where returns depend on clinical trial success and regulatory approval rather than current income.

CRNX performance versus SPY

Price and return data through 2026-09-02.

Total return is 246.6% over the past 8.1 years, 39.1 points ahead of SPY at 207.5%. Over the past year its total return — price change plus distributions reinvested — is 155.1%. Its deepest 1-year drawdown was 42.2%.

CRNX key facts

Asset type

Stock

Asset class

Equity

Inception date

07/18/2018

Distribution frequency

None

Last close

$84.95 (stale; as of 2026-09-02)

Market cap

$9,012,787,665

Average volume

0.0

Beta

0.088

Payout ratio

0.0%

EPS

$-5.05

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CRNX risks and drawbacks

The deepest 1-year drawdown on record here is 42.2%.

Who may consider CRNX — and who may not

It is a weaker fit for investors who need monthly cash flow (CRNX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on CRNX

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions